Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00243763 · ClinicalTrials.gov registry record · Phase 1
TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
A Phase 1 study, sponsored by Novartis.
- Terminated
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
NCT00243763 is a Phase 1 study that was terminated before completion, run by Novartis. The registered enrollment target is 64 participants.
The verdict
NCT00243763, a Phase 1 study, was terminated before completion, sponsored by Novartis.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
Study Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
Interventions
- DRUG TKI258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00243763
The ClinicalTrials.gov registry entry for NCT00243763 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TKI258 is the first listed.
NCT00243763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00243763 about?
NCT00243763 is a clinical study titled "TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma". The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
What is the current status of trial NCT00243763?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 64 participants.
What interventions are being tested in trial NCT00243763?
The interventions under investigation include: TKI258 (DRUG).
Who is sponsoring clinical trial NCT00243763?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.